Using Nafamostat Combined with Low-Intensity Heparin for Safer Anticoagulation in ECMO Treatment

What this Trial Is About

This research aims to improve anticoagulation management in patients undergoing extracorporeal membrane oxygenation ECMO due to severe respiratory failure. The study addresses the high rates of bleeding and clotting complications linked to ECMO, which significantly increase mortality. Optimizing anticoagulation strategies is critical to reducing these adverse events. Participants will be randomly assigned to one of two groups. The experimental group receives a combination of nafamostat and unfractionated heparin, with dosages adjusted to maintain specific clotting times both systemically and within the membrane oxygenator during ECMO. The control group receives unfractionated heparin alone, with dosage adjusted to maintain clotting times within a defined range. This approach aims to evaluate a novel regional anticoagulation strategy combined with lower intensity systemic anticoagulation. During the 28-day study period, participants will be monitored for bleeding and clotting events related to ECMO. Researchers will measure clotting times and track complications to assess the safety and effectiveness of both anticoagulation methods. This monitoring includes regular laboratory tests and clinical assessments throughout the ECMO treatment duration.

A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation